AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10930055 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium polystyrene sulfonate 30 g
Number of subjects: 6
Study 10930055 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 6
Study 8689424 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6) daily bolus therapy
Number of subjects: 12
Study 8689424 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6) continuous infusion (C.I.) therapy
Number of subjects: 12
Study 8689424 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6) bolus therapy
Number of subjects: 12
Study 8689424 — intervention group
Group type: COMPARATOR
Intervention: Control specimens
Number of subjects: 12
Study 1735142 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 53
Study 1735142 — intervention group
Group type: COMPARATOR
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 53
Study 1735142 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 53
Study 6389126 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Number of subjects: 441
Study 6389126 — intervention group
Group type: COMPARATOR
Intervention: Moxalactam
Number of subjects: 441
Study 31553410 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran (1 dose: 200, 300, or 500 mg on day 1)
Number of subjects: 501
Study 31553410 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran (2 doses: 100, 200, or 300 mg on days 1 and 90)
Number of subjects: 501
Study 31553410 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran (2 doses: 300 mg)
Number of subjects: 501
Study 31553410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study 31553410 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran (1 or 2 doses)
Number of subjects: 501
Study 29235159 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea ointment
Number of subjects: 99
Study 29235159 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 99
Study 29235159 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 99
Study 25995049 — intervention group
Group type: EXPERIMENTAL
Intervention: Small bowl
Number of subjects: 61
Study 25995049 — intervention group
Group type: COMPARATOR
Intervention: Large bowl
Number of subjects: 61
Study 24418526 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-screening group
Number of subjects: 4104
Study 24418526 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4104
Study 24418526 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-screening group (excluding CT costs)
Number of subjects: 4104
Study 24418526 — intervention group
Group type: EXPERIMENTAL
Intervention: True-positive group
Number of subjects: 4104
Study 24418526 — intervention group
Group type: EXPERIMENTAL
Intervention: False-positive group
Number of subjects: 4104
Study 22506760 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher energy treatment with cryogen spray cooling (CSC) (10‐mm spot size; 50 J/cm(2); 50‐ms pulse duration and CSC settings of 30‐ms duration with a 20‐ms delay)
Number of subjects: 22
Study 22506760 — intervention group
Group type: COMPARATOR
Intervention: Lower energy treatment with no CSC (10 mm; 20 J/cm(2); 50 ms)
Number of subjects: 22
Study 22506760 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 20159125 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk distance (6MWD) after a 7-week pulmonary rehabilitation program
Number of subjects: 75
Study 17506788 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent oxytocin infusion with dinoprostone pessary
Number of subjects: 0
Study 17506788 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone pessary alone (placebo)
Number of subjects: 0
Study 16159821 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated CPB circuits
Number of subjects: 12
Study 16159821 — intervention group
Group type: COMPARATOR
Intervention: Protein-coated CPB circuits
Number of subjects: 12
Study 12082182 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment using computer support to train patients to eat and recognize satiety, with physical activity restriction and resting in a warm room after eating.
Number of subjects: 32
Study 12082182 — intervention group
Group type: COMPARATOR
Intervention: Control group received no treatment.
Number of subjects: 32
Study 12082182 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment to remission.
Number of subjects: 32
Study 10460774 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone (IOAB with, 29 eyes)
Number of subjects: 63
Study 10460774 — intervention group
Group type: COMPARATOR
Intervention: No dexamethasone (IOAB without, 34 eyes)
Number of subjects: 63
Study 10460774 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone (IOAB with)
Number of subjects: 63
Study 10460774 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal dexamethasone (IOAB with) and No dexamethasone (IOAB without)
Number of subjects: 63
Study 8524724 — intervention group
Group type: EXPERIMENTAL
Intervention: Yearly preventive visits for 2 years and optional counseling visits to primary care provider
Number of subjects: 0
Study 8524724 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 2259930 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 0
Study 2259930 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 0
Study 2259930 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrazine sulfate
Number of subjects: 0
Study 2259930 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 0
Study 6626409 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication with diazepam 5 mg rectally and atropine 0.3‐0.4 mg sublingually (Group A)
Number of subjects: 80
Study 6626409 — intervention group
Group type: COMPARATOR
Intervention: Rectal solution including diazepam 0.5 mg kg‐1, morphine 0.15 mg kg‐1 and hyoscine 0.01 mg kg‐1 (Group B)
Number of subjects: 80
Study 31561882 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin added to standard of care (SoC)
Number of subjects: 0
Study 31561882 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC) alone
Number of subjects: 0
Study 29779922 — intervention group
Group type: EXPERIMENTAL
Intervention: NP-HA/FA (Nanopatch with split inactivated influenza virus applied to the volar forearm), n=15
Number of subjects: 60
Study 29779922 — intervention group
Group type: EXPERIMENTAL
Intervention: NP-HA/UA (Nanopatch with split inactivated influenza virus applied to the upper arm), n=15
Number of subjects: 60
Study 29779922 — intervention group
Group type: EXPERIMENTAL
Intervention: IM-HA/D (Intramuscular injection of Fluvax® 2016), n=15
Number of subjects: 60
Study 29779922 — intervention group
Group type: COMPARATOR
Intervention: NP-placebo/FA (Nanopatch with excipients only applied to the volar forearm), n=5
Number of subjects: 60
Study 29779922 — intervention group
Group type: COMPARATOR
Intervention: NP-placebo/UA (Nanopatch with excipients only applied to the upper arm), n=5
Number of subjects: 60
Study 29779922 — intervention group
Group type: COMPARATOR
Intervention: IM-placebo/D (Saline injected IM into the deltoid), n=5
Number of subjects: 60
Study 26674334 — intervention group
Group type: EXPERIMENTAL
Intervention: PACAP38 (n = 16)
Number of subjects: 24
Study 26674334 — intervention group
Group type: COMPARATOR
Intervention: VIP (n = 15)
Number of subjects: 24
Study 24464551 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (GS-7977)
Number of subjects: 32
Study 24464551 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-0938
Number of subjects: 32
Study 24464551 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Sofosbuvir and GS-0938
Number of subjects: 32
Study 22187253 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-emulsion propofol
Number of subjects: 36
Study 22187253 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 36
Study 22187253 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-emulsion propofol
Number of subjects: 36
Study 19558807 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dose ACTH therapy (50 IU per day for 2 weeks, then tapered to zero over 2 weeks)
Number of subjects: 30
Study 19558807 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose ACTH therapy (0.4 IU/kg per day for 2 weeks, then tapered to zero over 2 weeks; dosage increased to 1 IU/kg per day if no effective response)
Number of subjects: 30
Study 19558807 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose ACTH therapy
Number of subjects: 30
Study 19558807 — intervention group
Group type: COMPARATOR
Intervention: Low dose ACTH therapy
Number of subjects: 30
Study 19558807 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Conventional and Low dose ACTH therapy)
Number of subjects: 30
Study 19558807 — intervention group
Group type: COMPARATOR
Intervention: Both groups (initial 8 responders)
Number of subjects: 30
Study 19558807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryptogenic WS group
Number of subjects: 30
Study 17188044 — intervention group
Group type: COMPARATOR
Intervention: Untreated control eyes from six AMD studies
Number of subjects: 6
Study 16802302 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic temporal lobe epilepsy patients
Number of subjects: 46
Study 16802302 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 46
Study 14750227 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a pinhole aperture during the recording of pattern reversal visual evoked potentials
Number of subjects: 0
Study 11339019 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthyroid patients (pre-treatment)
Number of subjects: 50
Study 11339019 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthyroid patients (post-treatment)
Number of subjects: 50
Study 11339019 — intervention group
Group type: COMPARATOR
Intervention: Hyperthyroid patients (HRV analysis at rest)
Number of subjects: 50
Study 11339019 — intervention group
Group type: COMPARATOR
Intervention: Hyperthyroid patients (HRV analysis during deep breathing test)
Number of subjects: 50
Study 11339019 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 50
Study 8783690 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg on days 1‐5 and 10 (total dose, 24 mg/kg)
Number of subjects: 88
Study 8783690 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg on days 1‐5 and 10 (total dose, 18 mg/kg)
Number of subjects: 88
Study 8783690 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg on days 1‐4 and 10 (total dose, 15 mg/kg)
Number of subjects: 88
Study 8783690 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg for 10 days
Number of subjects: 88
Study 8783690 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg/kg total dose
Number of subjects: 88
Study 1623343 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion of the definitive prosthesis 2 weeks following expansion (immediate)
Number of subjects: 65
Study 1623343 — intervention group
Group type: COMPARATOR
Intervention: Insertion of the definitive prosthesis 6 months following expansion (delayed)
Number of subjects: 65
Study 6714287 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydergine special (1 x 4 mg)
Number of subjects: 0
Study 6714287 — intervention group
Group type: COMPARATOR
Intervention: Hydergine forte (2 x 2 mg)
Number of subjects: 0
Study 29953095 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal total mesorectumectomy (TA-TME)
Number of subjects: 34
Study 29953095 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic total mesorectumectomy (Lap-TME)
Number of subjects: 34
Study 28361573 — intervention group
Group type: EXPERIMENTAL
Intervention: YYIRT at 17:00 h
Number of subjects: 11
Study 28361573 — intervention group
Group type: COMPARATOR
Intervention: YYIRT at 07:00 h
Number of subjects: 11
Study 25840767 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized fentanyl (2 μg/kg)
Number of subjects: 0
Study 25840767 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine (0.1 mg/kg)
Number of subjects: 0
Study 23123043 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific medical food (400 ml daily for one week, high in protein and leucine, enriched with fish oil and specific oligosaccharides)
Number of subjects: 38
Study 23123043 — intervention group
Group type: COMPARATOR
Intervention: Iso-caloric/iso-nitrogenous product (Control group)
Number of subjects: 38
Study 23123043 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific medical food (Active group)
Number of subjects: 38
Study 21385346 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Strength Training (IMST)
Number of subjects: 69
Study 21385346 — intervention group
Group type: COMPARATOR
Intervention: SHAM treatment
Number of subjects: 69
Study 18206175 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate treatment (5 mg folic acid per day, 50 mg vitamin B6 per day, 1,000 microg vitamin B12 per day)
Number of subjects: 36
Study 18206175 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 36
Study 15898379 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial fluoride‐releasing adhesive
Number of subjects: 40
Study 15898379 — intervention group
Group type: COMPARATOR
Intervention: Control (standard adhesive)
Number of subjects: 40
Study 12949712 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency energy delivery to the gastroesophageal junction
Number of subjects: 64
Study 12949712 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 64
Study 11083735 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol treatment for 12 months
Number of subjects: 41
Study 8866582 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray ad libitum (n=45)
Number of subjects: 89
Study 8866582 — intervention group
Group type: COMPARATOR
Intervention: Nicotine nasal spray fixed dosage of 1 mg x h‐1 during the day (n=44)
Number of subjects: 89
Study 1503915 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitozantrone, 14 mg m‐2 intravenously every 3 weeks (n = 30)
Number of subjects: 60
Study 1503915 — intervention group
Group type: EXPERIMENTAL
Intervention: Megesterol acetate, 160 mg bd (n = 30)
Number of subjects: 60
Study 1503915 — intervention group
Group type: COMPARATOR
Intervention: Mitozantrone
Number of subjects: 60
Study 1503915 — intervention group
Group type: COMPARATOR
Intervention: Megesterol acetate
Number of subjects: 60
Study 6510459 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 6
Study 6510459 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline
Number of subjects: 6
Study 6510459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6510459 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination with terbutaline (Theophylline)
Number of subjects: 6
Study 6510459 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination with terbutaline (Enprofylline)
Number of subjects: 6
Study 31699167 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed infants
Number of subjects: 290
Study 31699167 — intervention group
Group type: COMPARATOR
Intervention: Breastfed infants (non-smoking mothers)
Number of subjects: 290
Study 31699167 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed infants (smoking mothers)
Number of subjects: 290
Study 31422671 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (EPA+DHA) at a dose of 4 g/d
Number of subjects: 0
Study 31422671 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (EPA only) at a dose of 4 g/d
Number of subjects: 0
Study 31422671 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (EPA+DHA or EPA-only)
Number of subjects: 0
Study 31422671 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (4 g/d)
Number of subjects: 0
Study 31422671 — intervention group
Group type: COMPARATOR
Intervention: EPA-only (4 g/d) in REDUCE-IT trial
Number of subjects: 0
Study 28420644 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete abstinence from smoking (n=70)
Number of subjects: 172
Study 28420644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent smoking (n=68)
Number of subjects: 172
Study 28420644 — intervention group
Group type: COMPARATOR
Intervention: Persistent smoking (n=34)
Number of subjects: 172
Study 28420644 — intervention group
Group type: COMPARATOR
Intervention: Comparison of abstainers to persistent smokers
Number of subjects: 172
Study 27075874 — intervention group
Group type: EXPERIMENTAL
Intervention: Interceptor LN (200 mg/m(2) alpha‐cypermethrin)
Number of subjects: 934
Study 27075874 — intervention group
Group type: COMPARATOR
Intervention: Conventional treated nets (CTN) (40 mg/m(2) alpha‐cypermethrin)
Number of subjects: 934
Study 27075874 — intervention group
Group type: EXPERIMENTAL
Intervention: Interceptor LN
Number of subjects: 934
Study 27075874 — intervention group
Group type: COMPARATOR
Intervention: CTN
Number of subjects: 934
Study 24773470 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational technique (n = 90)
Number of subjects: 181
Study 24773470 — intervention group
Group type: COMPARATOR
Intervention: Standard technique (n = 91)
Number of subjects: 181
Study 22967478 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality stimuli
Number of subjects: 15
Study 22967478 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative stimuli
Number of subjects: 15
Study 22967478 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative physical stimuli
Number of subjects: 15
Study 22967478 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive stimuli
Number of subjects: 15
Study 18849014 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hyperplastic polyps
Number of subjects: 1637
Study 18849014 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal hyperplastic polyps
Number of subjects: 1637
Study 18849014 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal hyperplastic polyps
Number of subjects: 1637
Study 18849014 — intervention group
Group type: COMPARATOR
Intervention: Subjects without hyperplastic polyps
Number of subjects: 1637
Study 17519148 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormonal contraceptive vaginal ring (CVR) delivering Nestorone (NES) and ethinyl estradiol (EE) (150/15 microg/day)
Number of subjects: 45
Study 17519148 — intervention group
Group type: COMPARATOR
Intervention: Combined oral contraceptive (OC) providing levonorgestrel (LNG) and ethinyl estradiol (EE) (150/30 microg per tablet)
Number of subjects: 45
Study 17519148 — intervention group
Group type: COMPARATOR
Intervention: Comparison of CVR and OC
Number of subjects: 45
Study 15550579 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene
Number of subjects: 1035
Study 15550579 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 1035
Study 11258118 — intervention group
Group type: EXPERIMENTAL
Intervention: General internal reference prices
Number of subjects: 144
Study 11258118 — intervention group
Group type: EXPERIMENTAL
Intervention: Seller context
Number of subjects: 144
Study 11258118 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific internal reference prices
Number of subjects: 144
Study 9034228 — intervention group
Group type: EXPERIMENTAL
Intervention: NOCTE (1 x 30 mg at 21.00 h)
Number of subjects: 20
Study 9034228 — intervention group
Group type: EXPERIMENTAL
Intervention: BID (15 mg at 21.00 h and 15 mg at 09.00 h)
Number of subjects: 20
Study 9034228 — intervention group
Group type: COMPARATOR
Intervention: NOCTE and BID
Number of subjects: 20
Study 8379508 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 mg beta-carotene, 900 mg vitamin C, and 200 mg alpha-tocopherol for 6 months
Number of subjects: 22
Study 8379508 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 22
Study 8379508 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin supplements)
Number of subjects: 22
Study 3092836 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-514 (20 mg twice a day for 7 days)
Number of subjects: 10
Study 3092836 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice a day for 7 days)
Number of subjects: 10
Study 30151705 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical debridement, 0.12% chlorhexidine mouthwash, and Lactobacillus reuteri (probiotic agent)
Number of subjects: 50
Study 30151705 — intervention group
Group type: COMPARATOR
Intervention: Mechanical debridement and 0.12% chlorhexidine mouthwash (control group)
Number of subjects: 50
Study 30151705 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus reuteri)
Number of subjects: 50
Study 30151705 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control for probiotics)
Number of subjects: 50
Study 28848182 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF given during all 6 chemotherapy cycles
Number of subjects: 167
Study 28848182 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF limited to the first 2 chemotherapy cycles
Number of subjects: 167
Study 28848182 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (both groups)
Number of subjects: 167
Study 25456153 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein-enriched egg yolk with skimmed milk (n = 25)
Number of subjects: 92
Study 25456153 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein-enriched egg yolk with buttermilk (n = 23)
Number of subjects: 92
Study 25456153 — intervention group
Group type: COMPARATOR
Intervention: Traditionally prepared buttermilk without egg yolk (n = 21)
Number of subjects: 92
Study 25456153 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditionally prepared buttermilk with egg yolk (n = 23)
Number of subjects: 92
Study 25456153 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein-enriched egg yolk groups (both buttermilk and skimmed milk)
Number of subjects: 92
Study 24811959 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lens (SCL)
Number of subjects: 24
Study 24811959 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid gas-permeable lens (RGPL)
Number of subjects: 24
Study 24811959 — intervention group
Group type: COMPARATOR
Intervention: Spectacle wear
Number of subjects: 24
Study 22654449 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride citrate (15 mg) with 2 L PEG solution
Number of subjects: 250